1 Min Read
Oct 12 (Reuters) - Mirati Therapeutics Inc
* Mirati Therapeutics’ mocetinostat included in stand up to cancer’s cutting-edge clinical trial initiative for NSCLC patients Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.